|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 20 |
| 2 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet . 2010 (9742)2010，，9742： | 6 |
| 3 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 4 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 2 |
| 5 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)显示文摘 | Wasaburo Koizumi Yeul Hong Kim Masashi Fujii Hoon Kyo Kim Hiroshi Imamura Kyung Hee Lee Takuo Hara Hyun Cheol Chung Taroh Satoh Jae Yong Cho Hisashi Hosaka Akihito Tsuji Akinori Takagane Mikito Inokuchi Kazuaki Tanabe Tatsuya Okuno Mariko Ogura Kazuhiro Y | 2014 | Journal of Cancer Research and Clinical Oncology2014，，2： | 2 |
| 6 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | 2010 (9742)2010，，9742： | 2 |
| 7 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 8 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 9 | Introduction to International Commer- cial Arbitration in China 显示文摘 | Taroh Inoue | 2006 | Hong Kong Law Journal2006，36，： | 1 |
| 10 | Space-time codes for high data rate wireless communication: performance criterion and code construction 显示文摘 | Taroh V Seshadri N Calderbank A R | 1998 | IEEE Trans lnf Theory1998，44，2： | 1 |
| 11 | Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms显示文摘 | Taroh Satoh Takashi Ura Yasuhide Yamada Kentaro Yamazaki Toshimasa Tsujinaka Masaki Munakata Tomohiro Nishina Shu Okamura Taito Esaki Yasutsuna Sasaki Wasaburo Koizumi Yoshihiro Kakeji Naoki Ishizuka Ichinosuke Hyodo Yuh Sakata | 2011 | Cancer Science2011，，10： | 1 |
| 12 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 13 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 14 | Molecular genetics of paroxysmal nocturnal hemoglobinuria显示文摘 | Norimitsu I Yoshiko M Taroh K | 2003 | Int J Hematol2003，77，： | 1 |
| 15 | Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial显示文摘 | Yasuhide Yamada Daisuke Takahari Hiroshi Matsumoto Hideo Baba Masato Nakamura Kazuhiro Yoshida Motoki Yoshida Shigeyoshi Iwamoto Ken Shimada Yoshito Komatsu Yasutsuna Sasaki Taroh Satoh Keiichi Takahashi Hideyuki Mishima Kei Muro Masahiko Watanabe Yuh Sak | 2013 | Lancet Oncology2013，，13： | 1 |
| 16 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)显示文摘 | Kei Muro Narikazu Boku Yasuhiro Shimada Akihito Tsuji Shinichi Sameshima Hideo Baba Taroh Satoh Tadamichi Denda Kenji Ina Tomohiro Nishina Kensei Yamaguchi Hiroya Takiuchi Taito Esaki Shinya Tokunaga Hiroyuki Kuwano Yoshito Komatsu Masahiko Watanabe Ichin | 2010 | Lancet Oncology2010，，9： | 1 |
| 17 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer显示文摘 | Taroh Satoh Yasuhide Yamada Kei Muro Hidetoshi Hayashi Yasuhiro Shimada Daisuke Takahari Keisei Taku Takako Eguchi Nakajima Xiaojin Shi Kathryn H. Brown Narikazu Boku | 2012 | Cancer Chemotherapy and Pharmacology2012，，2： | 1 |
| 18 | A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer显示文摘 | Hidetoshi Eguchi Hiroaki Nagano Shogo Kobayashi Koichi Kawamoto Hiroshi Wada Naoki Hama Yoshito Tomimaru Hirofumi Akita Daisuke Sakai Taroh Satoh Toshihiro Kudo Fumiaki Isohashi Masaki Mori Yuichiro Doki | 2014 | Cancer Chemotherapy and Pharmacology2014，，2： | 1 |
| 19 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial显示文摘 | Yung-Jue Bang Eric Van Cutsem Andrea Feyereislova Hyun C Chung Lin Shen Akira Sawaki Florian Lordick Atsushi Ohtsu Yasushi Omuro Taroh Satoh Giuseppe Aprile Evgeny Kulikov Julie Hill Michaela Lehle Josef Rüschoff Yoon-Koo Kang | 2010 | The Lancet2010，，9742： | 1 |
| 20 | Lagrangian motion of air parcels in the stratosphere in the presence of planetary waves显示文摘 | Taroh Matsuno | 1980 | Pure and Applied Geophysics PAGEOPH1980，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员